Gong, Jun http://orcid.org/0000-0001-8713-1406
Kim, Daniel M.
Freeman, Michael R. http://orcid.org/0000-0001-8142-3432
Kim, Hyung
Ellis, Leigh http://orcid.org/0000-0003-4739-5049
Smith, Bethany
Theodorescu, Dan http://orcid.org/0000-0002-8708-8206
Posadas, Edwin
Figlin, Robert
Bhowmick, Neil
Freedland, Stephen J. http://orcid.org/0000-0002-8104-6419
Article History
Accepted: 5 October 2023
First Online: 14 November 2023
Competing interests
: J.G.: consulting or advisory role — EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas and Amgen. D.T.: consulting or advisory role — Aurora Oncology, Machavert Pharmaceuticals, Merck and Urogen Pharma. E.P.: consulting or advisory role — CytoLumina, Genentech/Roche, Janssen Oncology, Janssen Oncology and Novartis; speakers’ bureau — Bayer; research funding — Pfizer; patents, royalties, other intellectual property — patent on NanoVelcro Assay for circulating tumour cells in prostate cancer; and travel, accommodations, expenses — TRACON Pharma. R.F.: leadership — 4Dx and Apollomics; consulting or advisory role — Bristol-Myers Squibb, CBT Pharmaceuticals and Johnson & Johnson; and research funding — Bristol-Myers Squibb (institution), Calithera Biosciences (institution), Exelixis (institution), Merck (institution) and Peloton Therapeutics (institution). N.B.: leadership — Kairos Pharma Lmt. and Armida Labs, Inc; consulting — TRACON Pharma, Cellgene and Xencor; research funding — Xencor. S.J.F.: consulting or advisory role — Merck, Astellas, AstraZeneca, Pfizer, Janssen, Bayer, Clovis, Sanofi, Myovant and Exact Sciences. All other authors declare no competing interests.